Rare copy number variants contribute to congenital left-sided heart disease by Hitz, M.P. et al.
Rare Copy Number Variants Contribute to Congenital
Left-Sided Heart Disease
Marc-Phillip Hitz1,2, Louis-Philippe Lemieux-Perreault3, Christian Marshall4, Yassamin Feroz-Zada3,
Robbie Davies5, Shi Wei Yang1, Anath Christopher Lionel4, Guylaine D’Amours6, Emmanuelle Lemyre6,
Rebecca Cullum7, Jean-Luc Bigras1, Maryse Thibeault1, Philippe Chetaille8, Alexandre Montpetit9,
Paul Khairy3, Bert Overduin10, Sabine Klaassen11, Pamela Hoodless7, Mona Nemer12,
Alexandre F. R. Stewart13, Cornelius Boerkoel14, Stephen W. Scherer4, Andrea Richter6,
Marie-Pierre Dube´3, Gregor Andelfinger1*
1Cardiovascular Genetics, Department of Pediatrics, Centre Hospitalier Universitaire Sainte Justine, Universite´ de Montre´al, Montre´al, Que´bec, Canada, 2Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, 3Adult Congenital Heart Centre, Montreal Heart Institute, Universite´ de Montre´al, Montre´al,
Que´bec, Canada, 4 The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada, 5University
of Ottawa Heart Institute, Ottawa, Ontario, Canada, 6 Service of Medical Genetics, Department of Pediatrics, Centre Hospitalier Universitaire Sainte Justine, Universite´ de
Montre´al, Montre´al, Que´bec, Canada, 7 Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada, 8Cardiology Service, Centre Me`re-
Enfants, Centre Hospitalier Universitaire de Que´bec, Universite´ de Laval, Que´bec City, Que´bec, Canada, 9Genome Quebec Innovation Centre, McGill University, Montre´al,
Que´bec, Canada, 10 European Molecular Biology Laboratory–European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom,
11 Experimental and Clinical Research Center, Max-Delbru¨ck-Center for Molecular Medicine, Berlin, Germany, 12Department of Biochemistry, Microbiology, and
Immunology, University of Ottawa, Ottawa, Ontario, Canada, 13 Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario,
Canada, 14Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
Abstract
Left-sided congenital heart disease (CHD) encompasses a spectrum of malformations that range from bicuspid aortic valve
to hypoplastic left heart syndrome. It contributes significantly to infant mortality and has serious implications in adult
cardiology. Although left-sided CHD is known to be highly heritable, the underlying genetic determinants are largely
unidentified. In this study, we sought to determine the impact of structural genomic variation on left-sided CHD and
compared multiplex families (464 individuals with 174 affecteds (37.5%) in 59 multiplex families and 8 trios) to 1,582 well-
phenotyped controls. 73 unique inherited or de novo CNVs in 54 individuals were identified in the left-sided CHD cohort.
After stringent filtering, our gene inventory reveals 25 new candidates for LS-CHD pathogenesis, such as SMC1A, MFAP4, and
CTHRC1, and overlaps with several known syndromic loci. Conservative estimation examining the overlap of the prioritized
gene content with CNVs present only in affected individuals in our cohort implies a strong effect for unique CNVs in at least
10% of left-sided CHD cases. Enrichment testing of gene content in all identified CNVs showed a significant association with
angiogenesis. In this first family-based CNV study of left-sided CHD, we found that both co-segregating and de novo events
associate with disease in a complex fashion at structural genomic level. Often viewed as an anatomically circumscript
disease, a subset of left-sided CHD may in fact reflect more general genetic perturbations of angiogenesis and/or vascular
biology.
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Introduction
Left-sided congenital heart disease (LS-CHD) is one of the most
prevalent and severe cardiac malformations. The spectrum
includes bicuspid aortic valve (BAV), aortic valve stenosis (AS),
coarctation of the aorta (CoA) and hypoplastic left heart syndrome
(HLHS). Several observations, such as familial clustering as well as
statistical evidence from heritability analyses, suggest that LS-
CHD is strongly determined by genetic factors [1–3]. Linkage
analyses have revealed several significant loci in BAV, HLHS and
other forms of LS-CHD, as well as interrelatedness of subsets of
BAV and HLHS [4–6]. In human and mouse models, mutations
in key cardiac regulators (e.g, NOTCH1, NKX2–5, GATA5) can
cause LS-CHD [7–9]. Genotype-phenotype correlations have
been established for syndromic conditions, often with highly
variable expressivity including LS-CHD as a feature, such as de
Lange, Holt-Oram and Jacobsen syndromes [10,11]. Recently,
structural genomic variants have been implicated in the patho-
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genesis of congenital heart disease, but the extent to which copy
number variants (CNVs) contribute to LS-CHD and its heritability
has not yet been examined in detail [12,13]. We sought to further
delineate the role of such variants and hypothesized that multiplex
families enriched in LS-CHD phenotypes exhibit rare, causative
CNVs not detectable by linkage analysis. The cohort was
assembled almost exclusively within the French-Canadian popu-
lation, which is characterized by a marked founder effect and has
previously led to the identification of numerous disease genes [14].
We surveyed 464 genomes/individuals in 59 multiplex families
and 8 trios of a pedigree-based LS-CHD cohort from Quebec
using the Affymetrix Genome-Wide Human SNP Array 6.0 array
[15]. We compared our results to those from a large control cohort
at the University of Ottawa Heart Institute (UOHI, N= 1582)
which had complete cardiovascular phenotyping [16].
Here, we report the results of the first family-based study of the
role of CNVs in LS-CHD and identify both cosegregating and de
novo CNVs enriched in angiogenesis with 25 novel candidate genes
that account for up to 10% of disease in our cohort.
Results
Cohort description
We accessed a biobank of patients and families with congenital
heart disease, centered on the recruitment of French-Canadian
multiplex families with LS-CHD [15]. From a total of 464 samples
in 67 families genotyped on the Affymetrix 6.0 platform, 174
(37.5%) members were affected with LS-CHD and 290 (62.5%)
were confirmed unaffected. A summary by lesion is provided in
Table 1 (detailed in Table S1). In 59/67 (83%) families, multiple
members were affected with cardiac conditions. In eight families,
only one member was affected. In multiplex families, the following
relationships between pairs of affecteds were observed: parent-
offspring N=71, sibships/half-sibships N= 30, more distant
relationships (grand-parent-grand-child, avuncular, cousins)
N= 73. Diagnoses were concordant in 13 multiplex families,
discordant in 27, and both concordant and discordant in 17. The
median number of affected individuals in multiplex families was
two, the maximum nine. A summary overview of the workflow is
given in Figure 1.
Measuring the CNV burden and disease association
We compared affected and unaffected individuals with respect
to number and size of CNVs, type of CNV (deletion or
duplication) and number of genes intersected. Among the LS-
CHD cohort, 6,956 autosomal CNVs were detected, amounting to
an average of 14.97 autosomal CNVs per individual. We did not
detect any statistically significant differences between affected and
unaffected individuals in the LS-CHD cohort for overall CNV
burden, CNV size, CNV type and number of genes intersected
(Table S2).
To search for enrichment of disease associated CNVs within the
identified CNVs of the LS-CHD cohort, we first compared
affected individuals to unaffected ones using a logistic regression of
three different scenarios, which were adjusted for family structure:
1) CNV duplication versus normal CNV state; 2) CNV deletions
versus normal CNV state; 3) both CNV duplications or deletions
versus normal CNV state. This approach identified 6 enriched
genomic loci (pools) of overlapping CNVs (Table S3). After
comparison to the well-phenotyped OHI control cohort and
public databases, only three pools remained (Figure S4, Table S4),
all of which were overlapping segmental duplications.
Next, we evaluated 147 CNVs found to be present only in
affected individuals of the LS-CHD cohort. After identical
comparisons with controls (Figure S4), 111 unique CNVs were
identified which were present only in affecteds. Of the 111 unique
CNVs, 73 CNVs remained unique (Table S4 and Figure S5) after
accounting for the removal of CNVs based on segmental
duplications, 37 as common variants and eight as false negative
and positive CNV calls. We found 6/73 of the CNVs to be de novo
occurrences in the pedigrees, 24/73 were inherited. For the
remaining 43/73 CNVs, ancestral information was not available
(minimum estimated CNV de novo transmission rate of the affected
individuals in 53 trios 0.023 and 41 unaffected trios 0.015). Both
gains (n = 38) and losses (n = 35) were identified (Table S5).
Gene inventory and prioritization
In order to describe a role for the genes intersecting within these
73 CNVs in cardiac development, we used PLINK to test for
pathway enrichment analysis [17]. Using a rigorous algorithm for
pathway enrichment analysis, we found that genes involved in
angiogenesis for all identified CNVs, but not other examined gene
sets, were significantly enriched in CNVs of affected individuals
(genic CNVs p= 0.00867, all CNVs p= 0.0076) (Tables S6 and
Author Summary
Congenital heart disease (CHD) is the leading malforma-
tion among all newborns, and one of the leading causes of
morbidity and mortality in Western countries. Left-sided
CHD (LS-CHD) encompasses a spectrum ranging from
bicuspid aortic valve to aortic stenosis and hypoplastic left
heart syndrome with familial clustering. To date, the
genetic causes for LS-CHD remain unknown in the majority
of patients. To determine the impact of structural genomic
variation in multiplex families with LS-CHD, we searched
for unique or rare copy number variants present only in
affected members of a multiplex family cohort (N
total = 464, N affected members = 174 (37.5%)) and absent
from 1,582 controls free from LS-CHD. A stringent filter
based on in silico prioritization and gene expression
analysis during development allowed us to identify genes
associated with LS-CHD. Our study revealed 25 new
candidate genes for LS-CHD, such as SMC1A, MFAP4, and
CTHRC1, and overlap with known syndromic loci. We
estimate that unique copy number variants contribute to
at least 10% of left-sided CHD cases, with a gene content
suggesting broader perturbations of angiogenesis at the
base of LS-CHD.
Table 1. Overview over lesions.
Isolated aortic stenosis 19 (10.9)
Isolated aortic root or ascending aorta dilation 20 (11.5)
Isolated BAV 17 (9.7)
Isolated mitral valve defect 13 (7.5)
Isolated CoA 5 (2.8)
More than one LS-CHD lesion 41 (23.6)
LS-CHD lesion and additional CVM 59* (33.9)
Total 174
Distribution of isolated and combined LS-CHD phenotypes. Percents are relative
to the total of 174 individuals with cardiovascular malformation.
*This number includes one case with hypoplastic left heart syndrome.
doi:10.1371/journal.pgen.1002903.t001
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S7). We next analyzed the gene content of the CNVs by three
different approaches in order to evaluate a possible role in
cardiovascular biology:
a.) We conducted in silico prediction of gene functionality based
on a training set of genes involved in angiogenesis [18]. Our
gene set showed three exact matches with the training dataset
(MAPK7, ADORA2B and ANG). We identified 26 genes which
were significantly enriched (p,0.05) in the LS-CHD cohort
(Table S8).
b.) We used serial analysis of gene expression (SAGE) libraries of
embryonic mouse heart libraries to search for genes with at
least 3-fold higher expression in the developing outflow tract
versus the atria and ventricles at E10.5 [19,20]. In 8 affected
individuals, unique CNVs intersected 16 such genes (Table
S9).
c.) We mined public databases for cardiac-specific function and/
or expression patterns of identified genes. Visual inspection of
in situ expression profiles in the developing mouse identified 19
genes with a strong expression level either in the valves or the
heart (Table 2) [20,21].
Using these three criteria, we identified 25 potential candidates
for LS-CHD present in at least two of the three prioritization
methods (Table 2). One example is CTHRC1, a Wnt cofactor that
selectively activates the Wnt/PCP pathway. This gene showed a
28-fold higher expression in the outflow tract versus the cardiac
chambers and was specifically expressed within developing valves
(Figure 2) [22,23]. Another example, MFAP4, is located within the
Smith-Magenis/Potocki-Lupski syndrome region, thought to be
an elastin-binding matrix protein involved in cell adhesion and
highly expressed in developing valves and great vessels (Figure 2)
[24]. Comparing our results with loci suggested by previous
studies, we find that only the locus on 10q22 containing
PLA2G12A overlaps with a locus identified in a linkage scan for
hypoplastic left heart syndrome [6]. This gene encodes a secreted
phospholipase A(2), is abundantly expressed in the heart and
inhibits the BMP-pathway through binding to SMAD-complexes
[25].
Overlap with syndromic loci
Since numerous genetic syndromes are associated with LS-
CHD, we searched for overlap between the 25 prioritzed
candidates and known loci of such syndromes (Figure 1) [26]. Four
regions were thus identified: X-linked Cornelia de
Lange (Xp11.22), Ellis-van-Creveld/Witkop/Wolfram syndrome
(4p16.1) and Potocki-Lupski syndrome (17p11.2). In addition, we
Figure 1. Summary overview of the workflow for CNV detection. Flowchart of sample analysis from recruitment to prioritization.
doi:10.1371/journal.pgen.1002903.g001
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also identified a de novo gain at the previously identified 1q21 locus
[27].
In family 5, we observed a gain at Xp11.22, encompassing
SMC1A, RIBC1, IQSEC2 and HSD17B10. FISH analysis revealed a
46, ins(X;9)(p11.22;q12) karyotype in the father (Figure 3 and
Figure 4). Mutations in SMC1A cause the X-linked form of
Cornelia de Lange syndrome, in which approximately 25% of
patients have CHD, including LS-CHD [28]. In family 43, we
detected a duplication on chromosome 4p16.2-16.1 (3817 kb)
encompassing 34 genes, including MSX1, EVC and EVC2. The
mother was the only individual exhibiting this CNV, all of her 3
children were healthy (Figure 3 and Figure 5). The observed
phenotype of aortic valve dysplasia differs from the described
cardiac features of Ellis van Creveld syndrome, and no phenotypic
overlap with Witkop/orofacial clefting syndromes was apparent
[29,30]. Interestingly, valvular involvement was described in
multiple individuals with Wolfram syndrome [30]. In family 8,
we detected an affected individual with a 4801 kb gain on
chr17p12-p11.2 matching the previously described Potocki-Lupski
locus [31]. Cardiac anomalies were present in 26% of the cases
with Potocki-Lupski Syndrome, including dilated aortic root, VSD
and bicuspid valve, which were all observed in our case [32]. A de
novo gain at the previously described 1q21.1 locus was found in an
individual with BAV, coarctation and ventricular septal defect in
family 54 [27]. Taken together, the inventory of the CNV regions
overlapping with known syndromic regions reinforces the func-
tional candidacy of the genes identified.
Transmission patterns
We next sought to determine whether segregation patterns of
CNVs containing the most highly prioritized 25 genes would
provide additional support for causality (Figure 1). We found that
five unique exon-overlapping CNVs segregated with an LS-CHD
phenotype in five different families (Figure 3).
In family 5, the ins(X;9)(p11.22;q12) was passed on from the
affected father to one affected child, but not to a second affected
child. Within this family, the severely affected child received
another unique variant from the mother, leading to a gain of the
PXDNL locus on chromosome 8. This gain was also found in the
maternal uncle of the index case known to have BAV. PXDNL/
VPO2, could not undergo the full prioritization workflow, since it is
a human-specific gene; high cardiovascular expression has been
described for this gene (Figure 3A) [33]. In family 54, we found an
inherited loss at the LIMS1 locus; targeted mouse models of LIMS1
exhibit cardiovascular phenotypes (Figure 3B) [34]. In addition,
this family also shows cosegregation of a rare gain on chromosome
3 (encompassing PARP14, HSPBAP1, DIRC2, SEMA5), however,
none of the genes contained within this CNV was prioritized in
Table 2. Identified candidate genes.
Gene name Endeavour SAGE enrichment Eurexpress/Genepaint Transmission pattern Genomic location
ANG/RNASE4 0.000376 nd + Inherited (244, 245) Chr14q11.2
MAPK7 0.000122 8.15 2 De novo (607) Chr17p11.2
NCOR1 0.000937 nd + De novo (607) Chr17p11.2
ADORA2B 0.00379 nd + De novo (607) Chr17p11.2
MFAP4 0.00288 11.64 + De novo (607) Chr17p11.2
COPS3 0.00379 nd + De novo (607) Chr17p11.2
FLII 0.00187 nd + De novo (607) Chr17p11.2
MSX1 0.0049 7.36 N/A De novo (599) Chr4p16
SREBF1 0.00786 nd + De novo (607) Chr17p11.2
SMC1A 0.00906 nd + Inherited (17, 20) ChrXp11.22
LIMS1 0.00496 nd + Inherited (389, 390) Chr2q12
CACNA1C 0.00734 nd + n/a(84) Chr12p13
CRMP1 0.0156 10.96 2 De novo (599) Chr4p16
RASD1 0.0107 12.83 2 De novo (607) Chr17p11.2
ERCC5 0.0139 5.65 2 Inherited (92,96) Chr13q33
ULK2 0.0287 nd + De novo (607) Chr17p11.2
PLA2G12A 0.0409 3.61 2 n/a(717) Chr10q22
NGEF 0.0454 nd + Inherited (106, 107) Chr2q37
GRPEL1 0.11 3.10 + de novo (599) Chr4p16
PRPSAP2 0.34 3.49 + De novo (607) Chr17p11.2
MTHFD2 0.84 6.14 + de novo (834) Chr2p13
EVC2 0.74 6.19 + De novo (599) Chr4p16
CTHRC1 0.17 27.85 + De novo (243) Chr8q22
ITGA10 0.00348 nd + De novo (390) Chr1q21
HSD17B10 0.0281 nd + Inherited (17, 20) chrXp11.22
Compilation of the 25 LS-CHD candidate genes fulfilling all selection criteria. From left to right: gene name; ENDEAVOUR in silico prioritization; fold overexpression in
SAGE experiments outflow tract versus atria/ventricles; in situ hybridization in mouse hearts at embryonic day E10.5; transmission pattern (individual IDs); genomic
location.
doi:10.1371/journal.pgen.1002903.t002
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our workflow. In families 18, 21 and 39, a single instance each of
vertical transmission of a rare, prioritized CNV was observed
(Figure 3D, 3E, 3F). Taken together, 4/5 families with transmis-
sion of a prioritized CNV showed discordant phenotypes, only
family 21 exhibited concordant phenotypes in both affecteds
(Figure 3E). A total of 12 patients in 5 families thus show
segregation of a rare, prioritized CNV with LS-CHD. In a further
five patients, occurrence of such CNVs was either de novo or could
not be evaluated further due to lack of ascertainment of ancestors
(Table 2). Taken together, CNVs fulfilling all selection criteria
were observed in 17/174 affecteds, suggestive of a disease-causing
contribution in 10% of our population.
Discussion
Previous studies have provided evidence for an important role of
CNVs in the pathogenesis of several developmental conditions,
including congenital heart disease. These studies have predomi-
nantly relied on identification of de novo CNVs in sporadic cases.
Here, we present the first family-based CNV study in LS-CHD, a
disorder characterized by familial clustering, reduced penetrance
and variable expressivity.
Based on a carefully phenotyped cohort recruited from the
French-Canadian founder population and a large number of
controls with cardiac evaluation, our findings provide several lines
of evidence for a strong association of novel CNVs with LS-CHD.
Four plausible syndromic regions and 25 candidate genes either
known to be involved in congenital heart pathogenesis or highly
likely to impact the risk for LS-CHD were identified.
The use of a family-based cohort allowed us to make use of
segregation patterns to strengthen the association between rare
CNVs and LS-CHD. In our cohort enriched for multiplex
families, CNVs can occur both on an inherited and on a de novo
basis, mostly with intrafamilial phenotypic variability of LS-CHD.
This is compatible with a model in which structural genomic
variation contributes to both heritability and variable expressivity
of this trait. Interestingly, the vast majority of causative CNVs
identified in our study qualify as private in nature, despite our
intentional selection bias towards multiplex families within a
founder population.
In our studies, we used a sequential filtering approach to
increase the biological plausibility of identified LS-CHD candidate
genes. Several lines of evidence support enrichment for genes
involved in angiogenesis in this disease spectrum. We identified a
significant enrichment for genes implicated in angiogenesis,
pointing to a role of disturbances in endothelial development in
disease pathogenesis. In silico analyses, SAGE libraries and mining
of public databases identified several known and novel cardiac-
specific candidate genes. The in situ expression patterns of
CTHRC1 and MFAP4 are striking examples for enrichment in
developing valve structures and endothelium. Interestingly, both of
these genes act in known pathways of valvulogenesis and are copy-
number gains, suggesting that mechanisms other than haploinsuf-
Figure 2. mRNA expression profile of CTHRC1 and MFAP4 in embryonic mouse heart. (a, b). In situ hybridizations for MFAP4 of a sagittal
section of a wild-type stage E 14.5 mouse heart (c, d) In situ hybridizations for CTHRC1 of a sagittal section of a wild-type stage E 14.5 mouse heart.
Both assays show a strong expression in the pulmonary valve (arrows) and aortic/mitral valve (arrowheads). Unlike CTHRC1 which is more restricted to
the valves and only weakly expressed in the endothelium of the aorta,MFAP4 shows a strong expression in the pulmonary artery and ascending aorta
(asterisks). Pictures are taken from Eurexpress (www.eurexpress.org).
doi:10.1371/journal.pgen.1002903.g002
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ficiency may contribute to disease pathogenesis in these two
examples. Moreover, CTHRC1 was found to be significantly
overexpressed in calcific aortic stenosis, underscoring that hits to
developmental genes may predispose to both early and adult onset
valve disease [35].
This evidence is further corroborated by the identification of a
novel role for known syndromic loci in LS-CHD. Overall, CNVs
intersecting with four known syndromic loci were identified, and
for all loci, cardiovascular phenotypes were reported. Our study
widens the genotype-phenotype correlations in these syndromes; of
note, none of the patients had been a priori suspected to manifest
the associated clinical phenotypes. We suspect that for these loci,
the gene dosage – phenotype correlations are not perfect, and that
they represent predisposing loci which require further hits for full
penetrance of specific clinical features. Taking family 54 as an
example, the most severely affected individual showed three
unique CNVs, two inherited (one gain, one loss) from the affected
father, plus a de novo gain overlapping the previously described
1q21 locus (Figure 3). One of the inherited CNVs intersected with
LIMS1, which plays an essential role in outflow tract development
through TGF-b signalling. Interestingly, the clinical phenotypes
within this family partially overlapped, strengthening the idea that
multiple hits explain reduced penetrance or variable expressivity.
Based on this observation, we speculate that other CNVs may also
buffer phenotypes; i.e., two antagonistic hits within a single
cascade may render cardiac development tolerant against pertur-
bations in an epistatic fashion. Such a model would also be
consistent with insight from animal studies in which modifier genes
can govern normal or abnormal cardiac development on certain
backgrounds [36]. As another example, endothelial-specific
knockout of GATA5 in mice leads to BAV in only 20% of the
offspring, compatible with the reduced penetrance even of strong
alterations of gene dosage [9]. Other mouse models - examples
include mice haploinsufficient for eNOS, Nkx2.5 and Tbx5 - also
display reduced penetrance of CHD traits, with complex gene-
dosage effects of interacting alleles [8,37,38]. Of note, our study
was designed to identify CNVs which would not be detectable by
linkage analysis, using an algorithm that prevented the discovery
of incompletely penetrant alleles since CNVs seen in unaffected
family members or the well-phenotyped control cohort were
Figure 3. Selected segregation patterns of CNVs in LS-CHD pedigrees. See legend at the bottom of the figure for explanation of symbols.
DNA numbers refer to Tables S1, S2, S3, S4, S5, S6, S7, S8, S9 for affected individuals in whom rare CNVs were identified. A.) In family 5, we identified a
maternally inherited gain overlapping PXDNL and a paternally inherited insertion der(9)ins(X;9)(p11.22;q12) overlapping the Cornelia de Lange
syndrome gene SMC1A in the severely affected propositus.(NB: Individual 2126 was not initially genotyped on the Affymetrix 6.0 panel and is
therefore not described). B.) The severely affected propositus in family 54 showed three different rare CNVs: a paternally inherited gain overlapping
SEMA5B, HSPBAP1, DIRC2 and PARP14, a paternally inherited loss of LIMS1, and a de novo partial duplication on chromosome1q21.1. C.) De novo
occurrence and non-transmission of a large CNV gain (3817 kb) on chr4p16 overlapping the Ellis van Creveld region on chromosome 4. D.), E.) F.)
Segregation of prioritized CNVs with disease in families 18, 21 and 39.
doi:10.1371/journal.pgen.1002903.g003
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excluded. Two limitations of our study need to be kept in mind:
first, our results do not exclude the possibility that additional,
incompletely penetrant CNVs play a role in LS-CHD; second, our
design could have missed CNVs containing important non-coding
sequences such as regulatory elements since we required further
validation through expression studies. Further studies with much
larger cohorts are warranted to dispose of sufficient power for the
detection of incompletely penetrant alleles, rare double hits and
gene deserts [39].
Strengths of our study comprise the stringent, uniform CNV
analysis workflow for both the LS-CHD as well as the control
cohort, which yielded similar results in respect to reported de novo
CNV transmission rates [40]. Importantly, we used a rigorous
approach limited to CNVs which were unique or statistically
enriched in our cases. All controls had adequate cardiac screening
to account for mild phenotypes not detectable by conventional
clinical examination. Furthermore, the founder character of our
cohort theoretically facilitates detection of recurrent hits; never-
theless, this was not the case with our current sample size. On the
other hand, several limitations of our study should be noted. At
this point, it is unknown whether a cohort enriched for multiplex
families with LS-CHD is in itself genetically distinct from a normal
population sample. Due to the high stringency of our filtering
mechanism, our design precludes the discovery of CNVs with
incomplete penetrance and may underestimate the true impact of
CNVs on LS-CHD. Furthermore, we recognize that adequate
CNV boundary calling remains an issue which will best be
resolved using NextGeneration sequencing in future studies.
Taken together, our study suggests that unique CNVs
contribute significantly to LS-CHD, and that the majority of
genetic events are of private nature. CNVs were found to
contribute to 10% of our LS-CHD cases after statistical, biological
and genetic validation. Combinatorial interactions between several
different genetic factors disturbing key developmental events in left
ventricular outflow tract development - such as angiogenesis – may
modify the risk for LS-CHD, with important implications for an
oligogenic origin for the entire spectrum of LS-CHD.
Future work should aim at more precisely defining gene
inventories in larger cohorts and at replication of combinatorial
hits in animal models. Insight gained from these studies will assist
in identifying the underlying pathophysiological mechanisms of
LS-CHD and help clarify the diversity of outcomes in individual
patients despite similar morphologies.
Materials and Methods
Ethics statement
The ethics committees of Sainte Justine Hospital Research
Center, University of Montreal, Centre Hospitalier Universitaire
de Que´bec, Universite´ de Laval, and University of Ottawa
approved the study protocol and all participants gave their
informed consent. The study was in accordance with the principles
of the current version of the declaration of Helsinki.
Figure 4. Karyotype der(9)ins(X;9)(p11.22;q12) in family 5. (a,b) FISH was performed on metaphase chromosomes obtained from peripheral
blood with a labeled BAC clone that mapped within the detected copy gain (RP11-52N6, red) and a control probe mapped to the Xp/Yp
pseudoautosomal region of the sex chromosomes (DXYS129 & DXYS153, green). Green dots show the control probe hybridized to the p arm of
chromosomes X and Y. Red dots show the RP11-52N6 BAC clone hybridized on chromosome X (white arrow heads) and in the heterochromatin of
chromosome 9 (white arrows). A star shows the normal chromosome 9. These results show that the copy gain is due to a der(9)ins(X;9)(p11.22;q12) in
both the father (a) and his son (b). (c). Chromosomal region of the insertion (X;9)(p11.22;q12) in the father and the son of family 5. Four RefSeq genes
are identified within this region IQSEC2, RIBC2, HSD17B10 and the Cornelia de Lange gene SMC1A. One larger and one smaller CNV have been
detected in the DGV database in this region.
doi:10.1371/journal.pgen.1002903.g004
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Figure 5. dup(4)(p16.1) in family 43. FISH was performed on metaphase chromosomes and nuclei obtained from peripheral blood with a labeled
BAC clone mapped within the detected copy gain (RP11-89K12, green) and a control probe mapped to 4p14 (RP11-332F10, red). (a) Two series of
adjacent green dots show the extra copy of the duplicated segment on chromosome 4. (b) The nucleus view with the three green dots showing three
copies of the region overlapping the Ellis van Creveld genes on chromosome 4 (c) Log 2 ratio for the large gain in Family 43 on chromosome 4. In
general, dots are scattered around 0 along the x-axis for, whereas the identified gain leads to a clear upward shift (d) Heatmap of the identified gain
on chromosome 4, each line refers to one individual. An orange row indicates two copies of the region whereas an extra copy leads to a gain in the
intensity (yellow line for the individual in family 43).
doi:10.1371/journal.pgen.1002903.g005
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LS-CHD cohort
We accessed a biobank of patients and families with congenital
heart disease, centered on the recruitment of French-Canadian
multiplex families with LS-CHD [15]. A detailed family history
(minimum three generations) was obtained from each proband,
and all participants provided informed consent. We used a
sequential sampling strategy described previously [1]. The
cohort was assembled almost exclusively within the French-
Canadian population, which is characterized by a marked
founder effect and has previously led to the identification of
numerous disease genes [14]. We surveyed 464 genomes/
individuals in 59 multiplex families and 8 trios of a pedigree-
based LS-CHD cohort from Quebec using the Affymetrix
Genome-Wide Human SNP Array 6.0 array. The average age
was 28 years. A total of 65 French-Canadian families and 2
additional Caucasian families were included in the study. None
of the pedigrees had inbreeding or marriage loops. The gender
distribution was in favor of males (females N= 223 (48%), males
N= 241 (52%)). Index cases with recognizable syndromes,
developmental delays and known cytogenetic abnormalities were
excluded from the study.
All participants were evaluated by clinical examination,
standard 12 lead electrocardiography as well as two-dimensional
echocardiography. In 15/464 cases, echocardiography was
unavailable. For 6 of these 15 cases, we instead relied on either
magnetic resonance imaging, cardiac catheterization or surgical
reports to determine phenotype status. For the remaining 9/15
cases, no morphological characterization was available. Standard-
ized two-dimensional and Doppler transthoracic echocardiograms
were obtained on all participants through commercially available
systems (Hewlett-Packard [Mississauga, Ontario] Sonos 5500,
Philips iE33 [Andover, Massachusetts], GE Vivid 7 or Vivid I
[Mississauga, Ontario]) according to previously published proto-
cols [1]. Additional anatomic or hemodynamic abnormalities were
also recorded. Aortic root dilation was defined as a deviation
above a Z score of 2 according to previously published normal
values for children or adults [41,42].
LS-CHD phenotypes were defined as bicuspid aortic valve or
other aortic valve disease, coarctation or hypoplastic left heart
syndrome. Other cardiovascular phenotypes included dilation of
the aortic root/ascending aorta, other cardiovascular malforma-
tions, as well as abnormal electrocardiogram/documented ar-
rhythmia. An overview of phenotypes in patients subsequently
identified to carry a disease-causing CNV is given in Table S2.
Control cohort
We accessed genotyping data of a previously described cohort
with coronary artery disease and myocardial infarction, the
Ottawa Heart Institute cohort, for control purposes [16]. A total
of 1582 well-phenotyped controls were used after exclusion of
those with LS-CHD, including BAV. Most importantly, subclin-
ical disease, such as asymptomatic bicuspid aortic valve, thus had
very little likelihood to escape detection. Moreover, the UOHI
cohort was genotyped on the same Affymetrix Genome-Wide
Human SNP Array 6.0 platform, with an identical data analysis
workflow for CNV detection. The UOHI cohort was matched
with respect to gender, but not age. All individuals (cases and
controls) in this cohort were used as controls for the detection of
rare copy number variants (CNV) and were subjected to the same
CNV detection workflow as the LS-CHD cohort. According to
2006 census data, 16% of the population in the Ottawa area, or an
estimated 253 individuals in our dataset, are of French-Canadian
descent [43].
Command Console 2.1 and Genotyping Console 3.0.2
quality control
A detailed overview of individual steps in the genotyping and
quality control workflow is given in Figure S1. LS-CHD families
and control samples were genotyped at the McGill University–
Ge´nome Que´bec Innovation Centre on the Affymetrix Human
Genome-Wide SNP Array 6.0. DNA samples from peripheral
blood were isolated with standard procedures and master DNA
plates were prepared. Following DNA quality determination and
sample preparationat the genome facility, cel files were created
using AffymetrixGeneChip Command Console software 2.1 and
Genotyping Console 3.0.2 (GTC, Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s protocol.
Exclusion of samples for CNV detection QC issues
We used GTC 3.0.2 with a setting of 10 kb and 5 consecutive
markers to detect CNVs. We excluded 11 samples that had
excessive CNV calls per sample (defined as three standard
deviations above the observed mean (49.62 calls per sample,
standard deviation 18.14)). The remaining 464 individual samples
from 67 families were used for subsequent CNV detection.
Admixture tests
In order to test for the familiarity within the LS-cohort samples
we used Principal Component Analysis (PCA, see Figure S2) [44].
In short, a k-means procedure with 270 samples was used to get
the centers of the JPT+CHB, CEU and YRI samples. We
projected the first two axes onto the axes running between CEU-
JPT+CHB and CEU- YRI centers and formed an oval in the
projected space whose major axes were 10 times the length of the
standard deviation of CEU cluster along that axis. Samples falling
outside the oval were removed. A visual depiction of this process is
represented in Figure S3. The returned samples are most likely
family derived without a clear European axis. The first and the
second component of the PCA were used in the regression analysis
to adjust for family structure in the identification of enriched CNV
regions.
CNV identification, validation, and assessment
The analysis was performed using a stringent quality control
and copy number detection workflow with a merge procedure
relying on two different algorithms for both cohorts (Birdsuite
1.5.5 and GTC 3.0.2) (Figures S1, S4 and S5). Variants meeting
the following criteria were retained: 1.) CNVs $20 kb, 2.) CNVs
either unique or statistically enriched after accounting for
relatedness in affected versus unaffected individuals of the LS-
CHD and versus the UOHI cohort; 3.) We excluded common
CNVs found in the Database of Genomic Variants [45] (DGV
Freeze November 2010) 4.) CNVs had to show no more than 50%
overlap with known segmental duplications and had to be
confirmed by visual inspection. We further prioritized CNVs
based on biological plausibility (i.e. expression and pathway
analysis) and based on familial segregation with disease (Figure 1).
Figures S4 and S5 gives an overview over the workflow used for
CNV identification and validation, as outlined in detail below.
CNV detection workflow and validation
We used a merge procedure of two algorithms to detect CNVs:
a) GTC 3.0.2 (Affymetrix) with a setting of minimally 5
consecutive markers/10 kb and b) Birdsuite 1.5.5 (Broad Institute)
using default settings (see Birdsuite website for detailed descrip-
tion). Both programs use SNP and copy number probes on the
Affymetrix 6.0 array to detect CNVs. CNVs call from GTC 3.0.2
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and Birdsuite 1.5.5 were merged using a Python script developed
in-house, keeping the outer boundaries for the individual CNV
calls. We used a script developed in house to convert Birdsuite’s
total number of copies on both homologous chromosomes into
values for gains and losses to accurately compare to the output of
GTC. For common and known CNPs (results from the Canary
algorithm), the mean number of copies (rounded to the closest
integer) of each CNP has been computed on all individuals (for the
reason that ‘‘normal’’ state of a CNP might not be two in a given
population). These integers for each CNP call were then compared
to gains and losses called by GTC. For rare or de novo CNVs
(results from Birdseye), each value has been compared to the
‘‘normal’’ state of two. Finally, we computed the percentage of
overlap for each CN segments found between GTC and Birdsuite
(with a confidence threshold of 10.0).
Initial validation focused on de novo calls of the autosomes by
visual inspection of the Heatmap and the log2 ratios on GTC 3.02.
This showed that the use of 50–100% overlap of the two outputs
with a size of .20 kb and a minimum of 5 consecutive probes in
the interval was the most reliable method in our hands to detect
true CNV calls on the autosomes. In addition, we randomly
selected 300 CNV calls from the LS-CHD cohort and examined
Heatmap intensities and log2 ratios to determine the presence of
the CNV. This gave a validation rate of.95%. Therefore we used
all CNVs identified in the 50–100% overlapping scenario for
subsequent analysis. Sex-chromosomal and autosomal CNVs were
analyzed independently (see section below). CNV locations and all
genomic coordinates given in this paper are based on the March
2006 Human reference sequence (NCBI build 36.1).
Analysis of identified autosomal CNVs
Plink 1.07 was used to generate pools of overlapping CNVs (–
segment-group). These CNV pools were then tested with SAS 9.2
for statistical evidence of enrichment in affected samples compared
to unaffected samples of the LS-CHD cohort. Three different
association models within our pools of overlapping CNVs were
evaluated: 1) Affected versus unaffected individuals were tested for
enriched CNV duplications in comparison to the normal CN state,
2) Similarly for deletions, 3) Similarly for the presence of a
duplication or a deletion. We fitted a logistic regression model in
SAS 9.2 using PROC GLIMMIX conditional on pedigree
membership for each CNV using family as a random effect and
the number of copies of CNVs as a fixed effect. The following
thresholds were used: a p-value less than 0.05 and those significant
after Bonferroni correction (9.346E-5 = 0.05/535). A minority of
tests did not converge and were tested using a one-sided Fisher
exact test.
The identified CNVs enriched in affected individuals along with
CNVs found to be uniquely present in affected individuals were
then grouped and compared to CNVs from the UOHI cohort. We
used Plink 1.07 (–segment-group) to search for overlapping CNVs
and tested for enrichment in LS-CHD affected compared to
UOHI samples by using a logistic regression model for each CNV
adjusted for the first two PCA components to adjust for ethnicity
and relatedness. We selected CNVs with a p-value less than 0.05
and those significant after Bonferroni correction (5.56E-3= 0.05/
9).
Plink 1.07 was used to generate a map file (–cnv-make-map).
Positions unique to affected individuals of the LS-CHD cohort in
the map file were selected and the referring CNV was evaluated
with an in house developed Python script for overlap with all
identified CNVs of the LS-CHD cohort. Previous studies have
highlighted the inaccuracies in determining CNV boundaries
using array technologies; these can ideally be addressed in detail
by next generation sequencing methods [46,47]. We therefore
examined the boundary calling of inherited CNVs to determine
the minimal overlap of seemingly identical CNVs. Identical CNVs
based on heatmap calls can vary up to 50% in their overlap when
comparing our two-algorithm merge. CNVs overlapping 50% or
less with any other CNV in the unaffected individuals of the LS-
CHD cohort were regarded as unique compared to the LS-CHD
affected individuals. Identified unique CNVs of the LS-CHD
cohort were evaluated for 50% overlap with the UOHI-cohort to
find CNVs unique to the affected of the LS-CHD cohort and
absent from the UOHI cohort. Only CNVs of the affected
individuals of the LS-CHD cohort not overlapping with any CNV
of the unaffected of the LS-CHD cohort and the UOHI cohort
were regarded as unique and were retained for analysis.
Analysis of sex-chromosomal CNVs
We found a high number of false positive CNV calls (75%) and
inaccuracies in calling CNVs on the sex-chromosomes, and opted
to visually inspect all CNVs identified in both algorithms in the
LS-CHD cohort on heatmaps and log2 ratios using GTC 3.0.2.
We used Plink 1.07 (–unique) to select CNVs unique to the
affected individuals of the LS-CHD cohort and absent from the
unaffected of the LS-cohort and the UOHI-cohort.
Final verification and validation of identified CNVs
Autosomal and sex-chromosomal CNVs found to be uniquely
present in LS-CHD affected individuals and autosomal CNVs
found to be statistically enriched in LS-CHD affected individuals
were considered for further verification (n= 111 unique CNVs and
n=3 enriched CNV regions. We developed a python script to
exclude CNVs which were overlapping 50% or more with
segmental duplications (UCSC segmental duplications download-
ed in January 2011). To account for CNPs and common CNVs we
excluded CNVs present with a frequency of more than 0.01%
using PLINK 1.07, which roughly corresponds to one CNV in
public databases overlapping by 50% or more with our CNVs
(DGV database download on November 2010). We examined the
position of all identified CNVs in heatmaps and log2 ratios, and
CNVs with a minimum overlap of 50% in affected family
members were regarded as identical CNVs. CNVs present in
unaffected family members were removed (n = 8).
We further validated CNV calls made in our in silico workflow
by using fluorescence in situ hybridization (FiSH, for microdele-
tions.100 kb and duplications .1000 kb) and qPCR. CNV calls
were tested in parents and related affected individuals in the same
family and more than two independent healthy controls. For a
total of 27 calls in 134 individuals, we obtained a confirmation rate
of 100% for selected CNVs identified with our strategy (Table S5).
QPCR validation
The copy number changes identified in silico were validated
using TaqManGene Copy Number Assays (ABI, Streetsville, ON,
Canada) (Table S5). Primers and probes were designed on NCBI
genomic sequence (Build36) using the GeneAssist Copy Number
Assay Workflow Builder (http://www5.appliedbiosystems.com/
tools/cnv/). Each assay was run on quadruplicate samples of
genomic DNA. The probe of interest targeting the identified CNV
was a FAM dye-based assay; an internal VIC dye-based assay for
RNase P was the reference probe. In brief, 10 ng of gDNA,
1xTaqMan probe/primer of the region of interest and 1xTaqMan
probe/primer of the internal control in 1xTaqMan Universal
Master Mix in a 10 ml reaction was used. The reaction was
amplified on the Applied Biosystems7900HT SDS instrument for
2 min at 50uC, 10 min at 95uC, followed by 40 cycles of 15 sec at
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95uC and 60 sec at 60uC. Real-time data were collected by the
SDS 1.3.2 software. The relative quantification of the test
sequence versus the reference gene known to have two copies
for autosomal regions was utilized to determine the changes in
copy number at the location. Further evaluation of the data and
quality checking was done with the SDS 1.3.2 software. Data was
then exported as a text file to evaluate for copy number changes in
the CopyCaller software according to the manufacturer’s guide-
lines.
Fluorescence in situ hybridization
Metaphase chromosome spreads were prepared from peripheral
blood samples following standard cytogenetic protocols. FISH
experiments were performed using commercial probes (Cytocell,
Cambridge, UK; Abbott Molecular, Des Plaines, IL, USA), or
labeled BAC clones from the RP11 library (Centre for Applied
Genomics, Hospital for Sick Children, Toronto, ON, Canada),
selected according to their mapped position on the Human March
2006 Assembly (hg18) using the University of California at Santa
Cruz Genome Browser (Table S5). Slides were pretreated with 26
SSC, dehydrated in ethanol, and left to dry. Chromosomes were
denatured in a 70% formamide/26SSC solution and probes were
incubated at 75uC and 37uC before being applied to the slides.
Slides were then placed at 37uC overnight for hybridization. Post-
hybridization washes were performed in 0.46SSC, 26SCC and
PBS, and slides were counterstained with DAPI. Chromosomes
and probes signals were visualized with a fluorescence microscope
(Zeiss, Toronto, ON, Canada) equipped with specific filters. Ten
metaphases were scored for each individual, and additional nuclei
were examined to confirm duplications. Images were captured and
recorded with CytoVision (Genetix, San Jose, CA, USA).
Gene sets for comparison
Using the key words: ‘Angiogenesis, left ventricular, valve and
aortic valve, chondrocyte development and bone development’
gene subsets were downloaded (Table S6) from the Ingenuity
application in August 2010. An additional geneset was used from a
published list of genes derived from targeted mouse models with
cardiac phenotypes [48]. Our list of CNVs intersecting genes from
the affected and unaffected individuals was downloaded using a
Perl script accessing the Biomart interface at Ensembl (www.
ensembl.org).
Gene enrichment
To test for gene enrichment within the identified CNVs we used
an empirical significance test based on a regression framework (-
cnv-enrichment-test) implemented in PLINK 1.07. For compar-
ison we downloaded the glist-hg18 from the PLINK website.
Enrichment tests were done with respect to all CNVs and all genic
CNVs for the above mentioned gene subsets to identify a causal
relationship within the total number of identified CNVs in the
merge procedure (Table S7) [17].
Endeavour
In order to prioritize candidate genes for LS-CHD pathogenesis
we used the public Endeavour server [18]. The training dataset
used was the angiogenesis gene set derived from Inguinity (above),
since the gene content of the identified CNVs showed the best
match in enrichment testing. We note that the training dataset was
significantly enriched in the genes we found to be enriched in the
affected versus the unaffected individuals of the LS-CHD cohort.
Endeavour generates distinct prioritizations and fuses them into a
global ranking using order statistics. We selected the intersecting
genes of all our rare CNVs in the affected and unaffected
individuals and obtained a prioritization list. Genes passing a
threshold of p,0.05 were considered to play a role in disease
pathogenesis (Table S8).
SAGE (Serial Analysis of Gene Expression)
Sage heart libraries were collected from C57BL/6J mice at E
10.5. Related procedures and further analysis for SAGE libraries
were described in detail in [20,49]. Mouse homologs for the
human genes identified to interest with the CNVs of the affected
and unaffected individuals were obtained from Biomart. To filter
for genes with higher expression in the outflow tract (OT), we set a
threshold of 3-fold higher tag counts in the OT versus the atria
and ventricles. These genes were selected as possible candidate
genes for further analysis (Table S9).
Eurexpress/Genepaint
The presence of two large databases for in situ expression in
mice enabled us to search for specific expression patterns of
candidate genes in endothelium, heart and valves [19,21]. Using
Eurexpress and Genepaint databases, we identified available in situ
slides of developing mouse embryos at ED 14.5 and visually
inspected all available candidate genes. Genes with an elevated
expression in the developing heart, valves or vessels were thus
identified (Table 2).
Supporting Information
Figure S1 Flowchart for quality control Affymetrix .cel files.
(EPS)
Figure S2 Principal components analysis (PCA). Principal
components were calculated for all unduplicated samples using
autosomal SNPs. Comparison of LS-CHD cohort showed a cluster
among the CEU samples. The control cohort was also scattered
around the CEU samples. With some samples of both cohorts
either along the axis of the YRI or JPY+CHB samples.
(TIF)
Figure S3 PCA k-means procedure. We used a k-means
procedure to remove outliers. Outlier are marked as red crosses
and have not been used in the downstream analysis.
(TIF)
Figure S4 CNV identification workflow. The combination of
Birdsuite 1.5.5 and GTC 3.0.2 revealed a total of 7087 CNV calls
in the merge procedure of the LS-CHD cohort and 20708 in
OHI-cohort.
(EPS)
Figure S5 CNV identification workflow. Hierarchical logistic
regression together with principal component analysis(PCA) and
selection of unique CNV calls in the affected identified 3 enriched
pools of CNVs and 110 autosomal and sex-chromosomal CNVs.
27 CNVs calls have been independently verified either by QPCR
or by Fish. 73 Unique calls in the affected of the LS-CHD cohort
were identified after removal of overlap with common CNVs and
segmental duplications. None of the enriched CNV pools was
considered for further analysis, since all three overlapped
segmental duplications.
(EPS)
Table S1 Clinical characteristics of all affected individuals in the
LS-CHD cohort with a rare CNV. Abnormal echocardiographic
or electrocardiographic results are recorded.
(XLSX)
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Table S2 CNV burden and de novo transmission rate. The
CNV burden (number of autosomal CNVs, number of segments/
sample, average segment size, and number of genes spanned by
CNV) is given for affecteds and unaffecteds. De novo CNVs were
determined within all available trios of examined families.
(XLSX)
Table S3 CNV Regions enriched in LS-CHD cohort. A fitted
logistic regression model in SAS 9.2 using PROC GLIMMIX
conditional on pedigree membership for each CNV with family as
a random effect and the number of copies of CNVs as a fixed
effect was used. P-values less than 0.05 and those significant after
Bonferroni correction were taken.
(XLSX)
Table S4 CNV Regions enriched after adjusting for family
structure and comparison with OHI cohort. The first and the
second component of the PCA were used in the regression analysis
to adjust for family structure in the identification of enriched CNV
regions.
(XLSX)
Table S5 Full list of unique inherited and de novo CNV
identified in affected individuals with LS-CHD using stringent
selection criteria.
(XLSX)
Table S6 LS-CHD related gene subsets for enrichment test.
Gene subsets for key processes involved in LS-CDH were
downloaded from Ingenuity.
(XLSX)
Table S7 Pathway analysis. An empirical significance test based
on a regression framework was used for enrichment testing of the
LS-CHD pathway genes relative to all and all genic CNVs.
(XLSX)
Table S8 Endeavour prioritization list for the LS-CHD cohort.
The enriched angiogenesis dataset was used to prioritize candidate
genes for LS-CHD pathogenesis to generate a global ranking using
order statistics.
(XLSX)
Table S9 SAGE analysis for genes identified in the LS-CHD
cohort. The mouse homologues for the human genes intersecting
rare CNVs were filter for enriched expression in the outflow tract
versus ventricle and atrium in developing mouse hearts.
(XLSX)
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